ZP GENERAL PARTNER 1 ApS: Financial statements 2019
CVR: 36402660
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
ZP GENERAL PARTNER 1 ApS (CVR 36402660) has filed annual accounts for 2019. In 2019, the company reported a net result of USD -2,000 compared with USD -1,000 the year before. Equity in the 2019 report amounted to USD 12,000. The solvency ratio was 85.7%.
- Profit/Loss
- USD -2,000
- Equity
- USD 12,000
- Total Assets
- USD 14,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | - | -2K USD | 12K USD | - |
| 2018 | - | - | -1K USD | 2K USD | - |
| 2017 | - | - | -2K USD | 3K USD | - |
| 2016 | - | - | -3 USD | 5 USD | - |
| 2015 | 0 USD | 0 USD | -4 USD | 8 USD | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of October 25, 2019, Matthew Donald Dallas is registered as director of ZP GENERAL PARTNER 1 ApS.
As of October 25, 2019, Ivan Mourits Møller has stepped down as director of ZP GENERAL PARTNER 1 ApS.
ZP GENERAL PARTNER 1 ApS has published its annual report for 2018. The net result was DKK -1,000.
As of May 29, 2019, Ivan Mourits Møller is registered as director of ZP GENERAL PARTNER 1 ApS.
As of May 29, 2019, Emmanuel Dulac is registered as director of ZP GENERAL PARTNER 1 ApS.
As of May 29, 2019, Emmanuel Dulac is registered as director of ZP GENERAL PARTNER 1 ApS.
As of May 29, 2019, Britt Meelby Jensen has stepped down as director of ZP GENERAL PARTNER 1 ApS.
As of May 29, 2019, Mats Peter Blom has stepped down as director of ZP GENERAL PARTNER 1 ApS.
As of May 29, 2019, Emmanuel Dulac has stepped down as director of ZP GENERAL PARTNER 1 ApS.
About ZP GENERAL PARTNER 1 ApS
ZP GENERAL PARTNER 1 ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The company is owned by ZEALAND PHARMA A/S. In 2025, the company reported revenue of DKK 2,000 and a net result of DKK -26,000 compared with DKK -14,000 the year before. Equity in the 2025 report amounted to DKK 81,000.